Speedy Safety Healthy

Based in Hangzhou, China, Speedy Safety Healthy is engaged in the research, development, production, and sales of pharmaceutical products, catering to healthcare providers globally with a focus on specialized disease treatments. Founded in 2019 in Hangzhou, China, Speedy Safety Healthy operates in the pharmaceutical sector, specializing in the provision of Finished Drugs, APIs, and Intermediates. The company has engaged in three investment deals to date, with the most recent deal occurring on January 13, 2026. The founder's background in the pharmaceutical field contributes to the firm's strategic vision and operational efficiency.

SSH Pharm specializes in research, development, registration, production, and sales of Finished Drugs, Active Pharmaceutical Ingredients (APIs), and Intermediates. Their focus is on specialized diseases such as anti-infection, kidney disease, reproductive health, and surgical needs, serving a wide range of healthcare providers, including over 1,000 hospitals across various provinces in China, while also aiming for international market expansion. Revenue generation at SSH Pharm comes primarily through direct sales and partnerships with hospitals and healthcare institutions. Products are sold either directly or via wholesale arrangements, focusing on bulk orders to ensure essential medications are available for patients.

Their flagship products, which target specialized diseases, are integral to their sales strategy, although specific pricing is not disclosed. In March 2026, Speedy Safety Healthy secured Series B funding from Addor Capital and Zijin Venture Capital, the details of which are undisclosed. The company plans to leverage this funding to enhance its product pipeline, with upcoming launches aimed at addressing additional specialized health needs. Furthermore, SSH Pharm intends to expand its reach into international markets, targeting regions such as Southeast Asia and Europe by the end of 2026.